Advertisement
News
Subscribe to MDT Magazine News

Gene Haas Machining Technology Scholarship Fund Provides $50,000 to Focus: HOPE Machinist Training Institute (MTI)

February 24, 2011 3:39 am | by Society of Manufacturing Engineers | Comments

DEARBORN, Mich., February 22, 2011 — Success breeds success. And at Focus: HOPE, the momentum is building for young men and women pursuing careers in the machinist trades. The SME Education Foundation has provided $50,000 from the Gene Haas Machining Technology Scholarship Fund to...

HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009

February 24, 2011 3:37 am | by Bio-Medicine.Org | Comments

FRAMINGHAM, Mass. and SYDNEY, Feb. 24, 2011 /- HeartWare International, Inc. (Nasdaq: HTWR ; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenues of $20.9...

TOPICS:

Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors

February 24, 2011 3:37 am | by Bio-Medicine.Org | Comments

IRVINE, Calif. and GUANGDONG PROVINCE, China, Feb. 24, 2011 /- Masimo (Nasdaq: MASI ) and Royal Fornia Electronic Device Co., Ltd. jointly announce a worldwide technology licensing agreement to integrate Masimo rainbow SET® Pulse CO-Oximetry™ technology into Royal Fornia's new...

TOPICS:
Advertisement

NewCardio Study Shows CardioBip Detects Recurrent Atrial Fibrillation Earlier and More Reliably than Periodic Holter Monitoring(2)

February 24, 2011 3:36 am | by Bio-Medicine.Org | Comments

SANTA CLARA, Calif., Feb. 24, 2011 /- PR Newswire – NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited by the Heart Rhythm Society (HRS) to present results of a recent clinical study showing...

TOPICS:

Fatty liver may herald impending Type 2 diabetes

February 24, 2011 3:35 am | by EurekAlert | Comments

(The Endocrine Society) A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that individuals with fatty liver were five times more likely to develop Type 2 diabetes than those without fatty liver. This higher risk seemed...

TOPICS:

NewCardio Study Shows CardioBip Detects Recurrent Atrial Fibrillation Earlier and More Reliably than Periodic Holter Monitoring

February 24, 2011 3:35 am | Comments

SANTA CLARA, Calif., Feb. 24, 2011 /- PR Newswire – NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited by the Heart Rhythm Society (HRS) to present results of a recent clinical study showing...

Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science

February 24, 2011 1:37 am | by EurekAlert | Comments

(Vilcek Foundation) The Vilcek Foundation is pleased to announce the 2011 winners of its annual prizes honoring the contributions of foreign-born scientists and artists in the US. Titia de Lange, Ph.D., of Rockefeller University, takes the Vilcek Prize for Biomedical Science for...

TOPICS:

Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference

February 24, 2011 1:35 am | by Bio-Medicine.Org | Comments

BLUE BELL, Pa., Feb. 24, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO will present a company overview at the...

TOPICS:
Advertisement

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results

February 24, 2011 1:35 am | by Bio-Medicine.Org | Comments

THE WOODLANDS, Texas, Feb. 24, 2011 /- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three...

TOPICS:

Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer

February 23, 2011 10:35 pm | by Bio-Medicine.Org | Comments

WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar®...

TOPICS:

Volcano Reports Record Revenue and GAAP Profitability for 2010

February 23, 2011 10:33 pm | by Bio-Medicine.Org | Comments

SAN DIEGO, Feb. 23, 2011 /- Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, today reported record revenues for the...

TOPICS:

Prevalence of bunions increases with age; more common in women

February 23, 2011 7:37 pm | by EurekAlert | Comments

(Wiley-Blackwell) New research determined that an increase in the severity of hallux valgus, or bunion deformity, progressively reduced both general and foot-specific health related quality of life. Bunion deformity was found in 36 percent of the study population and occurred more...

TOPICS:

Monocrystal ships 8-inch C-plane sapphire substrates to leading LED maker

February 23, 2011 7:36 pm | by I-Micronews | Comments

Monocrystal, announced the shipment of its premium 8-inch C-plane epi-ready sapphire substrates to what the company says is one of the world?s leading LED manufacturers.

Transphorm emerges from stealth to redefine energy efficiency

February 23, 2011 7:36 pm | by I-Micronews | Comments

Company backed by $38 million from leading venture capital firms Kleiner Perkins, Google Ventures, Foundation Capital, and Lux Capital.

Social Networking's Newest Friend: Genomics

February 23, 2011 7:33 pm | by Massachusetts Institute of Technology | Comments

The first large-scale study to combine genome sequencing and social-network analysis solves a mysterious TB outbreak.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading